U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H31NO3.C6H8O7
Molecular Weight 525.5886
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PENTOXYVERINE CITRATE

SMILES

OC(=O)CC(O)(CC(O)=O)C(O)=O.CCN(CC)CCOCCOC(=O)C1(CCCC1)C2=CC=CC=C2

InChI

InChIKey=AKJDEXBCRLOVTH-UHFFFAOYSA-N
InChI=1S/C20H31NO3.C6H8O7/c1-3-21(4-2)14-15-23-16-17-24-19(22)20(12-8-9-13-20)18-10-6-5-7-11-18;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-7,10-11H,3-4,8-9,12-17H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

HIDE SMILES / InChI
Molecular Formula C6H8O7
Molecular Weight 192.1235
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C20H31NO3
Molecular Weight 333.465
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created using several sources including: http://www.ncbi.nlm.nih.gov/pubmed/3768695 | http://www.ncbi.nlm.nih.gov/pubmed/8057277 | https://www.drugs.com/cdi/solotuss-suspension.html | http://www.drugsupdate.com/generic/view/1197/Pentoxyverine

Pentoxyverine is a non-opioid antitussive used to prevent cough caused by common cold. It is used as an active ingredient of several oral over-the-counter cough suppressants alone or in combination with other medications, especially decongestants. Certuss is a combination of pentoxyverine and guaifenesin. Pentoxyverine is FDA pregnancy category C drug. Known as anticonvulsant, and spasmolytic agent.

CNS Activity

CNS Active
3913
Curator's Comment: Carbetapentane bindinding with high affinity to the in the brain of rats potentiated the effects of the prototypic antiepileptic drug diphenylhydantoin.

Approval Year

1955
116
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 75.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Phase I
428
Unknown

Approved Use

Unknown
Doses

Doses

DosePopulationAdverse events​
30 mg 3 times / day multiple, oral (mother), breasteeding (infant)
Overdose
Dose: 30 mg, 3 times / day
Route: oral (mother), breasteeding (infant)
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3371222
healthy, infant
n = 1
Health Status: healthy
Age Group: infant
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/3371222
Disc. AE: Respiratory failure...
AEs leading to
discontinuation/dose reduction:
Respiratory failure (acute, 1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/3371222
100 mg 1 times / day multiple, oral
Highest studied dose
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/32164969
unhealthy
Health Status: unhealthy
Condition: productive cough
Sources:
https://pubmed.ncbi.nlm.nih.gov/32164969
Sources:
https://pubmed.ncbi.nlm.nih.gov/32164969
AEs

AEs

AESignificanceDosePopulation
Respiratory failure acute, 1 patient
Disc. AE
30 mg 3 times / day multiple, oral (mother), breasteeding (infant)
Overdose
Dose: 30 mg, 3 times / day
Route: oral (mother), breasteeding (infant)
Route: multiple
Dose: 30 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/3371222
healthy, infant
n = 1
Health Status: healthy
Age Group: infant
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/3371222
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-0170
http://www.3bsc.com/index/pro_info.php?id=19526
AA Blocks
AA008NGW
https://www.aablocks.com/goods/Goods/detail?id=AA008NGW
AHH Chemical co.,ltd
API-1156
http://www.ahhchemical.com/product/API-1156.html
AK Scientific, Inc. (AKSCI)
K344
http://www.aksci.com/item_detail.php?cat=K344
Achemtek
0104-021321
http://www.achemtek.com/77-23-6
Alichem
19117081
http://www.alichem.com/en/products/77-23-6.html
Ambinter
Amb15692761
http://www.ambinter.com/reference/15692761
BLD Pharm
BD119984
http://www.bldpharm.com/products/77-23-6.html
BioSynth
W-104325
https://www.biosynth.com/en/products/chemical-intermediates/advanced-intermediates/products/W-104325.html
ChemMol
49401505
http://www.chemmol.com/chemmol/49401505.html
ChemMol
49425998
http://www.chemmol.com/chemmol/49425998.html
Chemspace
CSSB00020617750
https://chem-space.com/CSSB00020617750
Debye Scientific
DB-056191
http://www.debyesci.com/cas_77-23-6.html
Finetech
FT-0603066
http://www.finetechnology-ind.com/prod/detail/pub/77-23-6.html
Hairui
HR129976
http://www.hairuichem.com/en/product/77-23-6.html
Lab Network
LN00200057
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00200057
MolPort
MolPort-006-110-223
https://www.molport.com/shop/molecule-link/MolPort-006-110-223
Parchem
28451
http://www.parchem.com/chemical-supplier-distributor/Carbetapentane-018451.aspx
Selleck Chemicals
S0869
https://www.selleckchem.com/products/carbetapentane.html
Smolecule
S591881
https://www.smolecule.com/products/s591881
THE BioTek
bt-315140
https://www.thebiotek.com/product/others/bt-315140
eNovation Chemicals
Y1079688
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1079688
iChemical
EBD21767
http://www.ichemical.com/chemicals/cas-77-23-6
PubMed

PubMed

TitleDatePubMed
Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.
2000 May
A non-potentiometric sensing method for the determination of pentoxyverine with PQC sensors based on ion-pair complexes.
2001 Dec
Anti-proliferative activity of haloperidol in B16 mouse and human SK-MEL-28 melanoma cell lines.
2005 Oct
Effects of common antitussive drugs on the hERG potassium channel current.
2008 Dec
[Quantification of pentoxyverine citrate in human plasma by LC-ESI/MS method and its application].
2009 Dec
Patents

Patents

8877749
4
CA2372535
4
CN1660113
4
US6455727
4
US6586469
4
WO1992017177
4

Sample Use Guides

In Vivo Use Guide
Pentoxyverine citrate or hydrochloride salts for adults up to 180 mg/day can be prescribed in divided doses. Pentoxyverine should be taken with food
Route of Administration: Oral
In Vitro Use Guide
1-5 mg/kg inhibited citric-acid-induced cough in guinea-pigs
Substance Class Chemical
Created
by admin
on Fri Dec 15 16:13:26 UTC 2023
Edited
by admin
on Fri Dec 15 16:13:26 UTC 2023
Record UNII
4SH0MFJ5HJ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PENTOXYVERINE CITRATE
JAN   MART.   WHO-DD  
Common Name English
LOUCARBATE
Brand Name English
PENTOXYVERINE CITRATE [JAN]
Common Name English
TOCLASE
Brand Name English
PENTOXYVERINE CITRATE [MART.]
Common Name English
CARBETAPENTANE CITRATE
MI   VANDF  
Common Name English
CYCLOPENTANECARBOXYLIC ACID, 1-PHENYL-, 2-(2-(DIETHYLAMINO)ETHOXY)ETHYL ESTER, CITRATE (1:1)
Common Name English
ETHANOL, 2-(2-(DIETHYLAMINO)ETHOXY)-, 1-PHENYLCYCLOPENTANECARBOXYLATE (ESTER) CITRATE
Common Name English
PENTOXYVERINE HYDROGEN CITRATE [EP MONOGRAPH]
Common Name English
CARBETAPENTANE CITRATE [MI]
Common Name English
2-(2-(DIETHYLAMINO)ETHOXY)ETHYL 1-PHENYLCYCLOPENTANECARBOXYLATE CITRATE (1:1)
Systematic Name English
Pentoxyverine citrate [WHO-DD]
Common Name English
PENTOXYVERINE HYDROGEN CITRATE
Common Name English
NSC-757833
Code English
CARBETAPENTANE CITRATE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66917
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
Code System Code Type Description
RXCUI
283547
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY RxNorm
ECHA (EC/EINECS)
245-449-5
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY
CAS
23142-01-0
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY
DRUG BANK
DBSALT001543
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY
ChEMBL
CHEMBL73234
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY
EVMPD
SUB03695MIG
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY
FDA UNII
4SH0MFJ5HJ
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY
NCI_THESAURUS
C76472
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY
MERCK INDEX
m3065
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY Merck Index
NSC
757833
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY
MESH
C018861
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY
SMS_ID
100000090449
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY
EPA CompTox
DTXSID10177717
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY
PUBCHEM
90010
Created by admin on Fri Dec 15 16:13:26 UTC 2023 , Edited by admin on Fri Dec 15 16:13:26 UTC 2023
PRIMARY
Related Record Type Details
Structure of PENTOXYVERINE
PARENT -> SALT/SOLVATE
Structure of ANHYDROUS CITRIC ACID
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of PENTOXYVERINE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966